Document is current
Any future updates will be listed below
-
Authors
Theng, Elizabeth H.
Brewer, Carmen C.
Oheim, Ralf
Zalewski, Christopher K.
King, Kelly A.
Delsmann, Maximillian M.
Rolvien, Tim
Gafni, Rachel I.
Braddock, Demetrios T.
Jeffrey Kim, H.
Ferreira, Carlos R. https://orcid.org/0000-0002-2697-1046
-
Funding
Funding for this research was provided by:
National Institutes of Health
- License Information
-
More Information
Article History
Received: 14 January 2022
Accepted: 26 June 2022
First Online: 19 July 2022
Declarations
:
: All patients were enrolled in research protocols NCT00369421 and NCT00024804. These studies were conducted in accordance with the Declaration of Helsinki and protocols were approved by the NIH Institutional Review Board (IRB). All subjects or their guardians provided informed consent and assent when appropriate. Consent for publication is included within the research protocols.
: C.R.F. and R.I.G. report a collaboration with Inozyme Pharma, Inc as part of a Cooperative Research and Development Agreement. D.T.B. is an inventor of patents owned by Yale University for therapeutics treating ENPP1 deficiency. D.T.B is an equity holder and receives research and consulting support from Inozyme Pharma, Inc.
